BARDA Archives - EverGlade

BARDA

BARDA Previews TACTIC Program for Threat-Agnostic CBRN Therapeutics

The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a pre-solicitation notice for a potential future project opportunity: TACTIC, or Threat-Agnostic CBRN Therapeutics. The anticipated effort would support development of therapeutics that address host dysregulation caused by chemical, biological, radiological, and nuclear, or CBRN, threats. BARDA is […]

BARDA Previews TACTIC Program for Threat-Agnostic CBRN Therapeutics Read More »

BARDA Releases RFP for Pandemic Influenza Vaccine Medical Countermeasures

The Biomedical Advanced Research and Development Authority (BARDA) has released a new Request for Proposals, Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response. The solicitation seeks partners to support the development, manufacturing, stockpiling, regulatory readiness, and rapid deployment of influenza vaccine medical countermeasures during a pandemic or other public health emergency. BARDA’s objective is

BARDA Releases RFP for Pandemic Influenza Vaccine Medical Countermeasures Read More »

BARDA’s BioMaP-Consortium Seeks Vendor Managed Inventory Capabilities to Secure the Nation’s API Reserve

The Biomedical Advanced Research and Development Authority (BARDA), through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), has released Request for Project Proposals (RPP) 26-12-VMI, “Ensuring American Pharmaceutical Supply Chain Resilience through Vendor Managed Inventory Capabilities for Active Pharmaceutical Ingredients Used in Medical Countermeasure Finished Dose Form Drug Products.” Issued by the Administration for Strategic Preparedness and

BARDA’s BioMaP-Consortium Seeks Vendor Managed Inventory Capabilities to Secure the Nation’s API Reserve Read More »

BARDA’s Next Big Investment Play: Pandemic Preparedness And Domestic Manufacturing

The Biomedical Advanced Research and Development Authority (BARDA) has been telegraphing its priorities for years, but the latest cluster of moves makes the picture sharper: the U.S. is shifting from “buy vaccines when a crisis hits” to owning the infrastructure that keeps pandemic response on a hair trigger. Three signals stand out: A new pre‑solicitation

BARDA’s Next Big Investment Play: Pandemic Preparedness And Domestic Manufacturing Read More »

BARDA’s BioMaP Releases RPP on Domestic Manufacturing for Nitrile Gloves

ASPR And BARDA Move To Close The Nitrile Glove Gap The Biomedical Advanced Research and Development Authority (BARDA), through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP‑Consortium), has released a new Request for Project Proposals (RPP 26‑09‑Gloves) focused on Expansion of Domestic Manufacturing Capacity for Nitrile Gloves. ASPR’s Center for Industrial Base Management and Supply Chain (IBMSC)

BARDA’s BioMaP Releases RPP on Domestic Manufacturing for Nitrile Gloves Read More »

Sustaining Nitrile Glove Capacity With BARDA’s PPE Manufacturing Push

The Biomedical Advanced Research and Development Authority (BARDA), working through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP‑Consortium), has released a new Request for Project Proposals (RPP 26‑04‑NBR) focused on Sustainment of PPE Capacities – Nitrile Butadiene Rubber (NBR). ASPR’s Industrial Base Management and Supply Chain (IBMSC) is seeking projects that will sustain and strengthen domestic NBR

Sustaining Nitrile Glove Capacity With BARDA’s PPE Manufacturing Push Read More »

BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants

The Biomedical Advanced Research and Development Authority (BARDA) has quietly dropped a pre‑solicitation notice for a major, long‑term contract to sustain and expand the Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program, including the U.S. National Pre‑pandemic Influenza Vaccine Stockpile (NPIVS). The notice, posted July 30, 2026 under solicitation number 75A50126R00001, is

BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants Read More »

BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice titled “Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries” (BARDA-CBRN-07282026) to identify commercially available or near commercial technologies that address large-area skin loss from burns and traumatic injuries in a mass casualty setting. This notice is for

BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns Read More »

BARDA RRPV RFI Seeks Partners for BSL4 Studies and Support Services 

Overview of the Opportunity The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Information (RFI) titled “Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development (BSL4)”. Issued July 9, 2026, the RFI is a market research exercise to map out who can deliver preclinical and nonclinical

BARDA RRPV RFI Seeks Partners for BSL4 Studies and Support Services  Read More »

BARDA’s RFI Explores Repurposing Autoinjector Equipment for New Drug Delivery Devices 

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA) is looking at a specific problem: how to repurpose specialized equipment originally designed to manufacture an emergency autoinjector platform into a broader drug delivery solution. Through the Rapid Response Partnership Vehicle (RRPV), BARDA released a new Request for Information (RFI), “Repurposing Equipment

BARDA’s RFI Explores Repurposing Autoinjector Equipment for New Drug Delivery Devices  Read More »

BARDA Issues RFI on Adjuvanted Egg-Based Influenza Vaccine for Pandemic Preparedness 

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to

BARDA Issues RFI on Adjuvanted Egg-Based Influenza Vaccine for Pandemic Preparedness  Read More »

BARDA Seeks Input on Next-Generation High-Performance Antigen Diagnostics

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “High Performance Antigen Diagnostics.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to better understand the landscape of current and emerging high-performance immunoassay

BARDA Seeks Input on Next-Generation High-Performance Antigen Diagnostics Read More »

Scroll to Top